The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VALN | +64.71% | N/A | N/A | -65% |
| S&P | +14.5% | +93.32% | +14.09% | +59% |
Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.
Some recent dismal results for Valneva's vaccine looked bad. But there could be more to the story.
It's too soon to know what the full impact of omicron will be. But these vaccine makers could be particular winners.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $54.82M | 33.8% |
| Gross Profit | $27.46M | 74.8% |
| Gross Margin | 50.10% | 11.8% |
| Market Cap | $482.13M | -1.1% |
| Market Cap / Employee | $0.69M | 0.0% |
| Employees | 700 | 0.0% |
| Net Income | -$13.14M | 51.0% |
| EBITDA | -$8.91M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $189.35M | 34.4% |
| Accounts Receivable | $28.32M | -13.4% |
| Inventory | 72.5 | 38.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $174.03M | -13.2% |
| Short Term Debt | $57.13M | 136.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.74% | -7.4% |
| Return On Invested Capital | -28.42% | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.25M | 79.4% |
| Operating Free Cash Flow | -$7.83M | 82.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.02 | 1.46 | 2.90 | 2.43 | 2.17% |
| Price to Sales | 2.85 | 1.94 | 2.73 | 2.16 | -27.73% |
| Price to Tangible Book Value | 2.38 | 1.73 | 3.37 | 2.83 | 3.24% |
| Enterprise Value to EBITDA | -212.19 | -56.37 | - | ||
| Return on Equity | -3.7% | -7.6% | -43.8% | -36.5% | 103.03% |
| Total Debt | $224.60M | $223.99M | $228.08M | $231.16M | 2.89% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
